These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 17593897

  • 1. Neuraminidase antibodies and H5N1: geographic-dependent influenza epidemiology could determine cross-protection against emerging strains.
    Bermejo-Martin JF, Kelvin DJ, Guan Y, Chen H, Perez-Breña P, Casas I, Arranz E, de Lejarazu RO.
    PLoS Med; 2007 Jun; 4(6):e212. PubMed ID: 17593897
    [No Abstract] [Full Text] [Related]

  • 2. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.
    Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ.
    PLoS Med; 2007 Feb; 4(2):e59. PubMed ID: 17298168
    [Abstract] [Full Text] [Related]

  • 3. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
    Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM, Tumpey TM, Ross TM.
    Vaccine; 2008 Oct 03; 26(42):5393-9. PubMed ID: 18706956
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Can immunity induced by the human influenza virus N1 neuraminidase provide some protection from avian influenza H5N1 viruses?
    Gillim-Ross L, Subbarao K.
    PLoS Med; 2007 Feb 03; 4(2):e91. PubMed ID: 17298170
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice.
    Takahashi Y, Hasegawa H, Hara Y, Ato M, Ninomiya A, Takagi H, Odagiri T, Sata T, Tashiro M, Kobayashi K.
    J Infect Dis; 2009 Jun 01; 199(11):1629-37. PubMed ID: 19385735
    [Abstract] [Full Text] [Related]

  • 8. Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain.
    Droebner K, Haasbach E, Fuchs C, Weinzierl AO, Stevanovic S, Büttner M, Planz O.
    Vaccine; 2008 Dec 09; 26(52):6965-74. PubMed ID: 18848593
    [Abstract] [Full Text] [Related]

  • 9. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
    Itoh Y, Ozaki H, Tsuchiya H, Okamoto K, Torii R, Sakoda Y, Kawaoka Y, Ogasawara K, Kida H.
    Vaccine; 2008 Jan 24; 26(4):562-72. PubMed ID: 18164788
    [Abstract] [Full Text] [Related]

  • 10. Prior infection with an H1N1 swine influenza virus partially protects pigs against a low pathogenic H5N1 avian influenza virus.
    Van Reeth K, Braeckmans D, Cox E, Van Borm S, van den Berg T, Goddeeris B, De Vleeschauwer A.
    Vaccine; 2009 Oct 23; 27(45):6330-9. PubMed ID: 19840669
    [Abstract] [Full Text] [Related]

  • 11. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
    Pavlova SP, Veits J, Keil GM, Mettenleiter TC, Fuchs W.
    Vaccine; 2009 Jan 29; 27(5):773-85. PubMed ID: 19041677
    [Abstract] [Full Text] [Related]

  • 12. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M, Tao P, Li J, Zhou S, Guo D, Pan Z.
    J Virol Methods; 2008 Dec 29; 154(1-2):121-7. PubMed ID: 18789973
    [Abstract] [Full Text] [Related]

  • 13. Pre- or post-pandemic influenza vaccine?
    Osterhaus AD.
    Vaccine; 2007 Jun 28; 25(27):4983-4. PubMed ID: 17555851
    [No Abstract] [Full Text] [Related]

  • 14. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge.
    Haynes JR, Dokken L, Wiley JA, Cawthon AG, Bigger J, Harmsen AG, Richardson C.
    Vaccine; 2009 Jan 22; 27(4):530-41. PubMed ID: 19026705
    [Abstract] [Full Text] [Related]

  • 15. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
    Ichinohe T, Ainai A, Tashiro M, Sata T, Hasegawa H.
    Vaccine; 2009 Oct 23; 27(45):6276-9. PubMed ID: 19840660
    [Abstract] [Full Text] [Related]

  • 16. Generation and evaluation of an H9N1 influenza vaccine derived by reverse genetics that allows utilization of a DIVA strategy for control of H9N2 avian influenza.
    Wu R, Chen Q, Zheng L, Chen J, Sui Z, Guan Y, Chen Z.
    Arch Virol; 2009 Oct 23; 154(8):1203-10. PubMed ID: 19543688
    [Abstract] [Full Text] [Related]

  • 17. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses.
    Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Houser KV, Tumpey TM, Epstein SL.
    Vaccine; 2009 Nov 05; 27(47):6512-21. PubMed ID: 19729082
    [Abstract] [Full Text] [Related]

  • 18. [Influenza vaccination: NOW!].
    Heinzl S.
    Med Monatsschr Pharm; 2006 Nov 05; 29(11):389. PubMed ID: 17131684
    [No Abstract] [Full Text] [Related]

  • 19. Influenza and the challenge for immunology.
    Doherty PC, Turner SJ, Webby RG, Thomas PG.
    Nat Immunol; 2006 May 05; 7(5):449-55. PubMed ID: 16622432
    [Abstract] [Full Text] [Related]

  • 20. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes.
    Chen Y, Qin K, Wu WL, Li G, Zhang J, Du H, Ng MH, Shih JW, Peiris JS, Guan Y, Chen H, Xia N.
    J Infect Dis; 2009 Jan 01; 199(1):49-58. PubMed ID: 19032063
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.